Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors (TRX518-001)

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2017 by Leap Therapeutics, Inc.
Sponsor:
Collaborator:
Cancer Research Institute, New York City
Information provided by (Responsible Party):
Leap Therapeutics, Inc.
ClinicalTrials.gov Identifier:
NCT01239134
First received: November 9, 2010
Last updated: March 1, 2017
Last verified: March 2017
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2018
  Estimated Primary Completion Date: October 2018 (Final data collection date for primary outcome measure)